文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

IL-1R1与IL-18信号在老年小鼠骨髓增生异常综合征模型中调控间充质基质细胞

IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromes.
PubMed 文献 · Blood · 2025-01-01

研究显示MDS患者骨髓中IL-1家族细胞因子(含IL-18)水平上调,IL-1b与IL-18直接作用于原代骨髓间充质基质细胞(MSC),影响其支持造血干祖细胞和红系祖细胞的能力。在将NHD13Tg细胞移植入老年野生型小鼠建立的年龄匹配MDS小鼠模型中,靶向IRAK4和NLRP3的抑制剂逆转了功能异常MSC的增殖并增强其功能,IRAK4抑制还选择性抑制MDS克隆细胞而不伤及非MDS细胞。作者认为靶向IL-1信号可能通过针对潜在髓系恶性并经由骨髓MSC修复改变的骨髓微环境而有望用于MDS治疗。

要点

  • MDS患者骨髓中IL-1家族细胞因子(包括IL-18)水平上调
  • IL-1b和IL-18直接作用于原代骨髓MSC,影响其支持造血干祖细胞与红系祖细胞的能力
  • 在老年小鼠MDS模型中,IRAK4与NLRP3抑制剂逆转功能异常MSC的增殖并增强其功能

核心结论

  • 靶向IL-1信号可能通过针对潜在髓系恶性并经骨髓MSC修复改变的骨髓微环境而有望用于MDS治疗。

研究设计与样本

  • 研究使用高度纯化的原代骨髓来源间充质基质细胞(MSC),并将NUP98-HOXD13转基因小鼠(NHD13Tg)细胞移植入老年野生型小鼠建立年龄匹配的MDS小鼠模型。

主要发现

  • MDS患者骨髓样本中IL-1家族细胞因子(包括IL-18)水平上调。
  • IL-1b和IL-18均对MSC产生直接作用,影响其支持造血干祖细胞和红系祖细胞的能力。
  • 靶向IL-1受体1型减轻了老年小鼠的这些衰老表型。
  • 靶向IRAK4和NLRP3的抑制剂逆转了功能异常MSC的增殖并增强其功能。
  • IRAK4抑制选择性抑制MDS克隆细胞,同时不伤及骨髓中的非MDS细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS) are age-related diseases characterized by bone marrow (BM) dysfunction and an increased risk for developing acute leukemia. Although there is growing evidence that highlight the crucial role of the BM microenvironment (BMME) in MDS, the specific influence of inflammation on BMME changes and the potential benefits of targeting cytokines therapeutically remain to be elucidated. We previously found that interleukin-1 (IL-1) is a driver of aging phenotypes of the BMME and hematopoietic stem and progenitor cells (HSPCs). In this study, BM samples from patients with MDS demonstrated upregulated levels of IL-1 family cytokines, including IL-18. Using highly purified primary BM-derived mesenchymal stromal cells (MSCs), both IL-1b and IL-18 were found to exert direct effects on MSCs, thus influencing their ability to support HSPCs and erythroid progenitors. This confirms the significant involvement of both these IL-1 family cytokines in regulating the BM niche. Furthermore, targeting IL-1 receptor type 1 mitigated these aging phenotypes in older mice. We subsequently employed an age-appropriate murine model of MDS by transplanting NUP98-HOXD13 transgenic mice (NHD13Tg) cells into aged wild-type mice. Treatment with inhibitors that targeted IL-1 receptor-associated kinase 4 (IRAK4) and NOD-like receptor family pyrin domain containing 3 (NLRP3) reversed the proliferation of dysfunctional MSCs and enhanced their functionality. In addition, IRAK4 inhibition selectively suppressed MDS clonal cells while sparing non-MDS cells in the BM. These findings suggest that targeting IL-1 signaling holds promise for MDS treatment by addressing the underlying myeloid malignancy and restoring the altered BMME via BM-MSCs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kawano Y, Kawano H, LaMere MW, et al. IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromes. Blood. 2025. PMID: 39841001. doi:10.1182/blood.2024024818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。